Ongoing Clinical Trials for Pulmonary Vascular Disorder
Currently, there is 1 ongoing clinical trial investigating treatment options for pulmonary vascular disorder, a condition affecting the blood vessels in the lungs that can lead to increased pressure in the pulmonary arteries. This trial is being conducted across multiple European countries and is studying the effects of the medication Riociguat in patients with early-stage disease.
Clinical trial locations
- Austria
- France
- Germany
- Italy
Study on the Effects of Riociguat in Patients with Early Pulmonary Vascular Disease
This trial is investigating how Riociguat, a medication that helps relax and widen blood vessels, can benefit patients with early signs of pulmonary vascular disease. The condition affects the blood vessels in the lungs and, if left untreated, can progress to pulmonary arterial hypertension, which is characterized by high blood pressure in the lung arteries. The study lasts for 24 weeks and uses a double-blind design, meaning neither participants nor researchers know who receives the actual medication versus a placebo.
Who can participate:
- Both men and women with early pulmonary vascular disease can join the study
- Eligible patients must have specific measurements of pulmonary arterial pressure and resistance that indicate early disease. This includes either a mean pulmonary arterial pressure of 25 mmHg or higher with pulmonary vascular resistance between 2 and less than 3 WU, or slightly lower pressure readings if associated with connective tissue disease or inherited forms
- Participants should not have previously received specific medications for pulmonary arterial hypertension
- Patients may be taking other medications such as blood thinners, diuretics, digitalis, calcium channel blockers, or oxygen supplementation, as long as these treatments started at least one month before a heart test called right-heart catheterization
- Results from the right-heart catheterization test must be recent, ideally not older than one month, though this can be extended to six months if there have been no significant changes in the patient’s condition
Who cannot participate:
- Patients with conditions other than pulmonary vascular disease
- Patients outside the specified age range for the study
- Individuals belonging to vulnerable populations not included in the study design
What the trial involves:
The main goal of this research is to determine whether Riociguat can reduce resistance in the blood vessels of the lungs, which would make it easier for the heart to pump blood through them. The medication works at a molecular level by stimulating an enzyme called soluble guanylate cyclase, which helps blood vessels relax and improves blood flow.
Participants are randomly assigned to receive either Riociguat in tablet form or a placebo. Throughout the 24-week treatment period, researchers monitor several aspects of health, including changes in the ability to exercise, heart function, lung capacity, walking distance, and overall quality of life. At the end of the study, a final evaluation assesses how much these measurements have changed from the beginning.
Investigational drug: Riociguat (also known as MK-4836) is taken orally as a film-coated tablet. It is being studied specifically for its potential to treat early pulmonary vascular disease by reducing the pressure in lung blood vessels.
Summary
Currently, one clinical trial is actively recruiting patients with early pulmonary vascular disorder across four European countries: Austria, France, Germany, and Italy. This international collaboration reflects the recognition that early intervention may be beneficial for this condition. The trial focuses exclusively on Riociguat, a medication that works by relaxing blood vessels in the lungs, and aims to determine whether it can prevent or slow the progression from early disease to more serious pulmonary arterial hypertension. The study specifically targets patients who have not yet received treatment for this condition, providing important information about intervention at the earliest stages of disease.